This review discusses ACR dysregulation in PCa through both mutational and non-mutational mechanisms, illustrated by discussing how the functional consequences are highly context-dependent, varying with disease stage, prior treatment exposure, and tumor ancestry.
Abstract
Abstract ATP-dependent chromatin remodelers (ACRs) have emerged as central determinants of prostate cancer (PCa) progression and therapy resistance. Organized into 4 mechanistically distinct families (SWI/SNF, ISWI, CHD, and INO80/SWR), ACRs govern nucleosome positioning genome-wide and thereby occupy a central position in the epigenomic regulatory landscape that dictates where and when transcription factors, including the androgen receptor (AR), can engage chromatin. This review discusses ACR dysregulation in PCa through both mutational and non-mutational mechanisms. These are illustrated by discussing how the functional consequences are highly context-dependent, varying with disease stage, prior treatment exposure, and tumor ancestry. Loss of each of the tumor suppressors RB1, TP53, and PTEN generates specific ACR dependencies that are potentially therapeutically exploitable, including synthetic lethal relationships between PTEN deficiency and SWI/SNF ATPase activity. Across the spectrum of AR signaling states, from hormone-sensitive disease through therapy-resistant neuroendocrine and double-negative PCa subtypes, ACR complex composition and genomic targeting are continuously reprogrammed to enable and sustain lineage plasticity and endocrine therapy escape. Therapeutic strategies targeting SWI/SNF, ISWI, and INO80/SWR complexes are at varying stages of preclinical and clinical development and are attractive novel avenues to target therapy-resistant PCa.
These findings establish AR phase separation as a fundamental mechanism driving GC pathogenesis and propose co-targeting AR condensates and chromatin remodeling as a translatable therapeutic strategy.
Hua-Huan Liu, Yan-Xin Yao, Xiang-Nan Zhang et al.· Cell Death & Disease· 0 citations
This framework positions CARM1 as a context-conditioned signal-to-chromatin translator rather than a uniformly druggable oncogene, and may offer the most tractable route to clinical translation.
Lu-Yao Zhu, Ya-Jie Liang, Qi-Qi Mao et al.· Biochimica et biophysica act...· 0 citations
Lineage plasticity underlies therapeutic resistance in cancer1,2, yet the translational mechanisms that enable this phenotypic flexibility remain largely unknown. Here using prostate cancer as a model of lineage dependence, we performed unbiased small RNA sequencing and identified tRNA1Arg(UCU) as a regulator of lineag...
Y. Kim, Sonali Arora, D. Young et al.· Nature· 0 citations
Linker histone H1 has traditionally been regarded as a structural scaffold that stabilizes higher-order chromatin organization. Recent evidence, however, indicates that H1 variants are dynamic chromatin regulators with variant-specific functions in cancer. Among them, H1.2, encoded by H1-2 (formerly HIST1H1C), has emer...
Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment of homologous recombination (HR)-deficient tumors. Nevertheless, their clinical utility is often compromised by the emergence of resistance. Although genetic restoration of HR is a well-established resistance mechanism, emerging evidence...
Woori Bae, Eun A. Ra, Myon Hee Lee· Frontiers in Pharmacology· 0 citations
This review examines how BRN2 connects developmental neurogenesis to therapy-induced tumor reprogramming and integrates insights from neurodevelopment and direct lineage reprogramming to describe how BRN2 maintains stem-like and neuroendocrine transcriptional states.